Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Debt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on Invested CapitalReturn on Sales

Dr Reddys Laboratories (RDY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to 16.32%.

  • Dr Reddys Laboratories' EBIT Margin fell 60800.0% to 16.32% in Q4 2025 from the same period last year, while for Dec 2025 it was 26.93%, marking a year-over-year decrease of 23200.0%. This contributed to the annual value of 22.09% for FY2025, which is 21700.0% down from last year.
  • As of Q4 2025, Dr Reddys Laboratories' EBIT Margin stood at 16.32%, which was down 60800.0% from 20.75% recorded in Q1 2025.
  • In the past 5 years, Dr Reddys Laboratories' EBIT Margin registered a high of 26.26% during Q2 2023, and its lowest value of 2.76% during Q4 2021.
  • In the last 5 years, Dr Reddys Laboratories' EBIT Margin had a median value of 21.12% in 2024 and averaged 20.52%.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -133400bps in 2021, then surged by 169000bps in 2022.
  • Over the past 5 years, Dr Reddys Laboratories' EBIT Margin (Quarter) stood at 2.76% in 2021, then skyrocketed by 612bps to 19.66% in 2022, then increased by 22bps to 23.93% in 2023, then decreased by -6bps to 22.4% in 2024, then dropped by -27bps to 16.32% in 2025.
  • Its EBIT Margin was 16.32% in Q4 2025, compared to 20.75% in Q1 2025 and 22.4% in Q4 2024.